Print ArticleKinovate Life Sciences, Inc, a provider of tools for oligonucleotide synthesis and gene delivery, announced today that it will officially launch its new NittoPhase™ solid support for oligonucleotide synthesis at the TIDES meeting commencing in Boston on May 1st. The joint development of this solid phase support product was announced on November 8th, 2004 by Kinovate’s sole shareholder, Nitto Denko Corporation (Osaka, Japan), a leading multi-national polymer synthesis company and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), a leader in RNA-based drug discovery and development.
Through utilization of the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, Isis’ outstanding oligonucleotide synthesis and drug development expertise and the worldwide marketing and customer support operations of Kinovate Life Sciences, this new product promises to deliver significantly improved technical and economic outcomes for all segments of the oligonucleotide industry.
Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides.
NittoPhase™ has been rigorously tested at both small and large scales, and has been observed to exhibit superior characteristics and performance when compared to other solid supports currently on the market. NittoPhase™ has great potential to decrease manufacturing costs due to it’s significantly lower unit cost, as well as potentially higher yield and full length purity, reducing cost-of-goods. NittoPhase™ will be commercially available in two grades; NittoPhaseTOS™ for high loading applications, and NittoPhaseROS™ for lower loading applications. In this way, NittoPhase™ offers a solution for the entire spectrum of oligonucleotide synthesis applications.
“Kinovate Life Sciences aims to be a robust partner to both oligonucleotide manufacturers and drug development companies by providing NittoPhase™, a new support with superlative performance at a significantly reduced unit cost. In this way we see considerable potential to make it possible for players of all scales in this industry to meet both long and short term objectives of cost savings, and the eventual development of oligonucleotide drugs that are affordable to patients,” stated Dr. Kenji Matsumoto, President of Kinovate Life Sciences, Inc. “Through our strong collaborative relationship with Isis Pharmaceuticals, we have had access to the very highest standard of technical and analytical resources to ensure that NittoPhase™ will deliver unmatched performance.”
“Our internal testing and analysis of NittoPhase™ has clearly validated this product in terms of technical and cost performance. As a result of our partnership with Nitto Denko Corporation, Isis is pleased to incorporate NittoPhase™ into its own drug development operations going forward,” said B. Lynne Parshall, Executive Vice President and Chief Financial Officer of Isis Pharmaceuticals. “We look forward to participating in the success of NittoPhase™. Our product development partnership with Nitto Denko is another example of how Isis has used its expertise in RNA-based drug discovery and development to work with partners in bringing innovative products to the market.”
Source : PRWeb
Mail to a Friend
Link to this article
